Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era.
BACKGROUND:The incidence, treatment and outcome of patients with newly diagnosed gastrointestinal stromal tumour (GIST) were studied in an era known for advances in diagnosis and treatment. METHODS:Nationwide population-based data were retrieved from the Netherlands Cancer Registry. All patients with GIST diagnosed between 2001 and 2012 were included. Primary treatment, defined as any treatment within the first 6-9 months after diagnosis, was studied. Age-standardized incidence was calculated according to the European standard population. Changes in incidence were evaluated by calculating the... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Journal article |
Erscheinungsdatum: | 2019 |
Schlagwörter: | Humans / Gastrointestinal Stromal Tumors / Antineoplastic Agents / Digestive System Surgical Procedures / Registries / Incidence / Survival Rate / Adolescent / Adult / Aged / Middle Aged / Netherlands / Female / Male / Imatinib Mesylate |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-29177295 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://repository.icr.ac.uk/handle/internal/3139 |